Author(s):
Rodrigues, Miguel A. ; Barbolini, Giorgia ; Ferraz, Maria P. ; Borges, João P. ; Santos, José D. ; Lopes, Maria A.
Date: 2026
Persistent ID: http://hdl.handle.net/10362/206337
Origin: Repositório Institucional da UNL
Subject(s): Antimicrobial; Bone regeneration; Drug delivery system; Prokaryotic/eukaryotic co-culture; Bioengineering; Biomaterials; Biomedical Engineering
Description
Bacteria-mammalian cell co-cultures can provide information on host-cell responses to biomaterials under bacterial challenge that is not available from separate monocultures. This study established a two-stage osteogenic cell–Staphylococcus aureus co-culture for assessment of a previously developed dual and sequential drug delivery system (DDS) designed to release gentamicin followed by alendronate. MG-63 cells were initially exposed to (Formula presented) (Formula presented) CFU/ml of S. aureus for different periods. An inoculum of (Formula presented) (Formula presented) CFU/ml and a 2 h exposure were selected because MG-63 metabolic activity did not differ significantly from the monoculture control at this time point (p > 0.05). These conditions were subsequently transferred to primary human bone-marrow mesenchymal stromal cells. The DDS-containing co-culture exhibited an increasing resazurin signal over 16 d and maintained adherent cells with an organised F-actin cytoskeleton. On day 25, protein-normalised alkaline phosphatase activity was 40 mol µg−1 protein in the DDS-containing co-culture, compared with 5 mol µg−1 protein in the basal-medium control and 63 mol µg−1 protein in the osteogenic-medium control. The model supports preliminary assessment of mammalian-cell compatibility and osteogenic-associated activity during sequential drug release under an initial bacterial challenge.